SeraGas LSR is a dual-action therapy that combines Rabeprazole Sodium (EC) — a potent proton pump inhibitor (PPI) — with Levosulpiride (SR) — a prokinetic and dopamine D2 receptor antagonist. This combination effectively relieves acid reflux, functional dyspepsia, gastroparesis, and other upper GI motility disorders by reducing acid secretion and improving gastric emptying. Indications: SeraGas LSR is indicated in the management of: Gastroesophageal reflux disease (GERD) Functional dyspepsia Chronic gastritis Non-ulcer dyspepsia Delayed gastric emptying Peptic ulcer disease Bloating and epigastric discomfort Irritable Bowel Syndrome with upper GI symptoms Key Benefits: Dual Mechanism for Superior Relief: • Rabeprazole suppresses stomach acid effectively. • Levosulpiride enhances gastrointestinal motility and gastric emptying. Comprehensive GI Symptom Control: Targets acid-related pain, bloating, nausea, and early satiety. Effective in Functional Dyspepsia: Restores normal gastric motility and improves patient comfort. Sustained Release Action: Levosulpiride (SR) ensures prolonged symptom control throughout the day. Better Compliance: Single capsule convenience enhances adherence in long-term therapy.